

Neuland Laboratories Limited 11th Floor (5th Office Level), Phoenix IVY Building, Plot No.573A-III, Road No.82, Jubilee Hills, Hyderabad - 500033, Telangana, India.

Tel: 040 67611600 / 67611700 Email: neuland@neulandlabs.com www.neulandlabs.com

November 10, 2023

To BSE Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001

The National Stock Exchange of India Ltd Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we wish to inform you that the Board of Directors at their meeting held on even date, i.e. November 10, 2023, have approved a capital expenditure of ₹ 128 crores for enhancing capacity at our Unit 3 located at Survey No. 10, Plot No. 3-72, Gaddapotharam Village, Jinnaram Mandal, Sangareddy District Telangana State 502 319.

The requisite details are as under:

a) Existing Capacity (Unit 3)	305 KL
b) Existing Capacity Utilization (Unit 3)	62%
c) Proposed Capacity Addition	207 KL
d) Period within which the proposed	Expected to be available for commercial
capacity is to be added	production in approximately in 2 - 3 years.
e) Investment required	Rs. 128 Crs
f) Mode of financing	Internal Accruals and Debt
g) Rationale	To maintain and cater to the growing demand of
g) Rationale	our customers

This is for your information and records.

Thanking you,

Yours faithfully, For Neuland Laboratories Limited

Sarada Bhamidipati Company Secretary